Market revenue in 2023 | USD 911.2 million |
Market revenue in 2030 | USD 1,651.7 million |
Growth rate | 8.9% (CAGR from 2023 to 2030) |
Largest segment | Next generation sequencing |
Fastest growing segment | Next Generation Sequencing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Next Generation Sequencing, QPCR & Multiplexing, LOAC & RT-PCR, Protein Microarrays, DNA Microarrays |
Key market players worldwide | Johnson & Johnson, Illumina Inc, Novartis AG ADR, Roche, Koninklijke Philips NV, Qiagen NV, Agilent Technologies Inc, Abbott Laboratories, Thermo Fisher Scientific Inc, GE HealthCare Technologies Inc Common Stock |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to next generation cancer diagnostics market will help companies and investors design strategic landscapes.
Next generation sequencing was the largest segment with a revenue share of 36.95% in 2023. Horizon Databook has segmented the Germany next generation cancer diagnostics market based on next generation sequencing, qpcr & multiplexing, loac & rt-pcr, protein microarrays, dna microarrays covering the revenue growth of each sub-segment from 2018 to 2030.
Presence of German and Greek testing labs that carry out different diagnostic tests and chemo sensitivity testing for quantitation of circulating tumor cells is anticipated to contribute to revenue generation from this region in next generation cancer diagnostics market.
Moreover, every year, thousands of patients migrate to Germany from North America for medical care and alternative cancer treatment owing to its lower cost treatment as compared to other countries of EU.
The German Medical Diagnostics Centre with its extensive services offers a good platform for the use of tumor biomarker with analysis to test serums provided by prime suppliers in the German market, yielding promising results, in turn progressing the organization.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany next generation cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Germany next generation cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account